Event-Driven Stocks

LeonaBio, Inc.

LONANasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income−$102.3M−$100.9M−$125.5M−$104.0M−$64.0M−$20.0M
Net income−$105.6M−$96.9M−$117.7M−$95.6M−$54.9M−$20.0M
Total assets$92.2M$58.8M$160.2M$258.2M$332.0M$279.6M
Total liabilities$64.4M$13.9M$30.1M$23.0M$10.9M$5.3M
Equity$27.8M$44.8M$130.2M$235.1M$321.1M$274.3M
EPS (diluted)$-24.70$-25.19$-3.09$-2.53$-1.49—
Shares out.39.0M38.3M37.9M37.6M37.1M32.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−380.0%
Return on assets
−114.6%
Return on capital (ROCE)
−229.0%
Liabilities / assets
69.8%
Debt / equity
2.32×
Book value / share
$0.71
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-22.12distress
Accruals / assets
−65.0%clean
Piotroski F-Score
2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
46
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 1 warning● 1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202661,9551.6+6.8%
Apr 30, 202658,0041.6-26.0%
Apr 15, 202678,4251.9-21.7%
Mar 31, 2026100,2061.0+127.7%
Mar 13, 202644,0141.0+20.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.